Regenerative Medicine Market to Reach $531.7 Billion, Globally, by 2033 at 32.4% CAGR: Allied Market Research

News provided by

Aug 06, 2024, 04:57 ET

Rise in incidence of chronic diseases, increase in geriatric population and growth in acceptance of stem cell therapies are the major factors which drive the global market growth.

WILMINGTON, Del., Aug. 6, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Regenerative Medicine Market by Product Type (Cell Therapy, Gene Therapy, Tissue Engineering and Small Molecule & Biologic), Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material and Pharmaceutical), and Application (Cardiovascular, Oncology, Dermatology, Musculoskeletal, Wound Healing, Ophthalmology, Neurology and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the regenerative medicine market was valued at $32.1 billion in 2023, and is estimated to reach $531.7 billion by 2033, growing at a CAGR of 32.4% from 2024 to 2033.

Request Sample of the Report on Regenerative Medicine Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/391

Prime determinants of growth

Rise in incidences of chronic diseases and increase in geriatric population are the major factors that drive the growth of the regenerative medicine market growth. However, high costs of treatment hinder the market growth. Moreover, technological advancements and regulatory Support and funding offers remunerative opportunities for the expansion of the global regenerative medicine market.

Report coverage & details

Report Coverage	Details
Forecast Period	2024–2033
Base Year	2023
Market Size In 2023	$32.1billion
Market Size In 2033	$531.7 Billion
CAGR	32.4 %
No. Of Pages In Report	216
Segments Covered	Product Type, Material, Application, And Region.
Drivers	Rise In Incidences of Chronic Diseases
	Increase In Geriatric Population
	Growing Acceptance of Stem Cell Therapies
Opportunities	Technological Advancements
	Regulatory Support and Funding
Restraints	High Costs of Treatment
	Ethical And Safety Concerns

Segment Highlights

The cell therapy segment to maintain its leadership status during the forecast period

By product type, the cell therapy segment generated the highest revenue in the regenerative medicine market in 2023. Cell therapy is a cornerstone of regenerative medicine, leveraging the therapeutic potential of stem cells and other cellular materials to repair, replace, or regenerate damaged tissues and organs. By harnessing the regenerative properties of cells, this approach offers promising solutions for treating a wide range of diseases and injuries, improving patient outcomes and quality of life.

Want to Explore More, Connect to our Analyst - https://www.alliedmarketresearch.com/connect-to-analyst/391

The biologically segment to maintain its leadership status during the forecast period

By material, the biological segment generated the highest revenue in the regenerative medicine market in 2023. Biologically derived materials are increasingly sought after in regenerative medicine due to their compatibility with the body's natural healing processes. These materials, such as extracellular matrix scaffolds and growth factors derived from tissues or organisms, provide a supportive environment for cell growth, differentiation, and tissue regeneration. Their biocompatibility and bioactivity make them ideal candidates for promoting tissue repair and regeneration in various medical applications, driving their demand in regenerative therapies.

The oncology segment to maintain its leadership status during the forecast period

By application, the oncology segment generated the highest revenue in the regenerative medicine market in 2023. The growing prevalence of chronic diseases, particularly cancer, underscores the need for innovative treatment approaches like regenerative medicine. Cancer cases often result in tissue damage from treatments such as chemotherapy or surgery. Regenerative therapies offer promising solutions by harnessing the body's natural regenerative capacities to repair or replace damaged tissues, potentially improving patient outcomes and quality of life in cancer care.

For Purchase Inquiry - https://www.alliedmarketresearch.com/purchase-enquiry/391

Regional Outlook

The regenerative medicine market exhibits a promising regional outlook, with North America and Europe leading in terms of market share due to advanced healthcare infrastructure, supportive regulatory frameworks, and robust research and development activities. In contrast, the Asia-Pacific region is poised for rapid growth, driven by increasing healthcare expenditure, expanding biotechnology sectors, and rising awareness of regenerative therapies. Emerging economies in Latin America and the Middle East & Africa are also witnessing growing interest and investment in regenerative medicine technologies.

Key Players

Stryker Corporation
Zimmer Biomet Holdings Inc.
Medtronic Plc.
Athersys Inc.
Stem Cell Inc. (Bioheart Inc.)
Organogenesis Inc.
Integra Lifesciences Holdings Corporation
Acelity Holdings Inc.
Isto Biologics (Isto Biologics Medical Systems Inc.)
CryoLife Inc.

The report provides a detailed analysis of these key players in the global regenerative medicine market. These players have adopted different strategies such as expansion, acquisition, product approval, product launch and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

Recent Industry Development

In December 2023, The University of Toronto's Medicine by Design initiative and CCRM, a non-profit organization that supports the development and commercialization of regenerative medicines, announced a launch of new strategic alliance to unlock Toronto's potential as a world-leading ecosystem for regenerative medicine. The goal of the alliance is to create coordinated, end-to-end capacity that spans discovery through to clinical translation and commercialization.
In January 2021, Integra LifeSciences Holdings Corporation, a global leader in regenerative tissue technologies and neurosurgical solutions, announced that it has completed the previously disclosed acquisition of ACell, Inc. Acquiring ACell and its proprietary MatriStem UBM technologies will enable Integra to provide more comprehensive complex wound management solutions to address our customers' most pressing clinical challenges.
In August 2023, Gilead Sciences and Tentarix Biotherapeutics entered into three multi-year collaborations to leverage Tentarix's Tentacles platform for the discovery and development of innovative, multi-functional protein-based therapies for cancer and inflammatory diseases.
In December 2022, Integra LifeSciences Holdings Corporation, a global leader in regenerative tissue technologies and neurosurgical solutions, announced that it has successfully completed its acquisition of Surgical Innovation Associates (SIA) . This acquisition is a highly strategic move to enable us to achieve our aspirations to become a global leader and innovator of implant-based breast reconstruction (IBBR) procedures.

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected]
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter